MedTrace Logo

ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

NCT06825624 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 560

Last updated 2025-02-13

No results posted yet for this study

Summary

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and efficacy of HS-20093 in combination with other anti-cancer agents in patients with advanced metastatic colorectal cancer.

Conditions

  • Metastatic Colorectal Cancer (CRC)

Interventions

DRUG

HS-20093

administered as an IV infusion

DRUG

Bevacizumab

administered as an IV infusion

DRUG

5-FU

administered as an IV infusion

DRUG

Leucovorin

administered as an IV infusion

DRUG

Capecitabine

administered orally

DRUG

Oxaliplatin

administered as an IV infusion

Sponsors & Collaborators

  • Hansoh BioMedical R&D Company

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-03
Primary Completion
2026-10-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06825624 on ClinicalTrials.gov